The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
暂无分享,去创建一个
[1] A. Kishimura,et al. Specific adsorption of a β-lactam antibiotic in vivo by an anion-exchange resin for protection of the intestinal microbiota. , 2021, Biomaterials science.
[2] A. Kishimura,et al. Protection of gut microbiome from antibiotics: development of a vancomycin-specific adsorbent with high adsorption capacity , 2020, Bioscience of microbiota, food and health.
[3] R. Carman,et al. Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection. , 2018, Anaerobe.
[4] E. Le Chatelier,et al. Protection of the Human Gut Microbiome From Antibiotics , 2017, bioRxiv.
[5] Muthanna J. Ahmed,et al. Adsorption of quinolone, tetracycline, and penicillin antibiotics from aqueous solution using activated carbons: Review. , 2017, Environmental toxicology and pharmacology.
[6] S. Tzipori,et al. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. , 2016, Anaerobe.
[7] M. Henn,et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. , 2016, The Journal of infectious diseases.
[8] Frédéric Leroy,et al. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut , 2016, Front. Microbiol..
[9] N. Safdar,et al. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. , 2016, American journal of infection control.
[10] O. Mathieu,et al. Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] James Kinross,et al. The gut microbiota and host health: a new clinical frontier , 2015, Gut.
[12] J. de Gunzburg,et al. Oral DAV131, a Charcoal-Based Adsorbent, Inhibits Intestinal Colonization by β-Lactam-Resistant Klebsiella pneumoniae in Cefotaxime-Treated Mice , 2013, Antimicrobial Agents and Chemotherapy.
[13] Rafael Bargiela,et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach , 2012, Gut.
[14] H. Masur,et al. Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit , 2012, Critical care medicine.
[15] N. Secher,et al. Pulmonary artery and intestinal temperatures during heat stress and cooling. , 2012, Medicine and science in sports and exercise.
[16] T. Albertson,et al. Gastrointestinal decontamination in the acutely poisoned patient , 2011, International journal of emergency medicine.
[17] T. Arakawa,et al. Highly efficient renaturation of β‐lactamase isolated from moderately halophilic bacteria , 2004, FEBS letters.
[18] J. Bartlett,et al. A NTIBIOTIC -A SSOCIATED D IARRHEA , 2002 .
[19] R. Weinstein,et al. The Role of Colonization in the Pathogenesis of Nosocomial Infections , 1996, Infection Control & Hospital Epidemiology.
[20] J. Peris,et al. Renal and nonrenal clearances of ceftriaxone at the steady-state and its relation to plasma protein binding , 1995 .
[21] T. Albertson,et al. Activated charcoal--past, present and future. , 1986, The Western journal of medicine.
[22] I. Patel,et al. Pharmacokinetics of ceftriaxone in humans , 1981, Antimicrobial Agents and Chemotherapy.
[23] S. Phillips,et al. Capacity of the human colon to absorb fluid , 1978 .
[24] H. Knothe,et al. Impact of Cefotaxime and Ceftriaxone on the Bowel and Vaginal Flora after Single-Dose Prophylaxis in Vaginal Hysterectomy , 2012, Drugs.
[25] R. Weinstein,et al. The role of colonization in the pathogenesis of nosocomial infections. , 1996, Infection control and hospital epidemiology.
[26] S. Phillips,et al. Capacity of the human colon to absorb fluid. , 1978, Gastroenterology.